| مستخلص: |
Background When heart failure with reduced ejection fraction (HFrEF) and chronic kidney disease (CKD) co-exist, Renin angiotensin-aldosterone system inhibitors (RAASi) are often underutilized for the fear of worsening renal function (WRF). Telmisartan is a RAASi characteristic for a favorable renal profle, although data on its utility in HFrEF is limited. This study aimed to compare efcacy and tolerability of Telmisartan versus Enalapril in patients with HFrEF and CKD. Results This study randomized 107 patients with HFrEF and CKD to either Telmisartan (10–80 mg) or Enalapril (5–40 mg) daily. The achieved RAASi dose, dose reductions (DR) or dis-continuation (DC), death/Heart failure rehospi‑ talization (HFH), NYHA class and 6MWT were compared at 3- and 6-months. At 3- and 6-months, 93.5% versus 68.6% and 95.2% versus 72.9% were maintaining ≥50% of the target dose in the Telmisartan- versus Enalapril-group, respectively. Despite the higher achieved dose by 3- and 6-months, Telmisartan versus Enalapril was associated with less WRF (6.4% vs. 22.9%, p=0.022 and 7.3% vs. 13.6%, p=0.28) and fewer episodes of DR-DC (31.9% vs. 55.1%, p=0.018 and 35.7% vs. 56.5%, p=0.041), respectively. By the end of the study, there were 5 deaths in each group, yet, HFH occurred in 34.1% versus 55.3%, p=0.035, and NYHA class changed by −1 [−2, 0] versus 0 [−1, 1], p=0.017 in Tel‑ misartan- versus Enalapril patients, respectively. Within-group results showed improvement in 6MWT in Telmisartan-, and increase in diuretic requirements in Enalapril-group. Conclusions In patients with HFrEF and CKD, Telmisartan was better tolerated to uptitrate, caused less WRF, less HFH and showed better functional improvement compared to Enalapril. Clinical trial registration This study was prospectively registered on clinicaltrials.gov, with registration number (NCT04736329). [ABSTRACT FROM AUTHOR] |
Find this article in full text from Springer Verlag. 
Full Text Finder